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Cyclobutanone Mimics of Intermediates in Metallo-b-Lactamase
Catalysis
Martine I. Abboud,[a] Magda Kosmopoulou,[b] Anthony P. Krismanich,[c] Jarrod W. Johnson,[c]
Philip Hinchliffe,[b] Jrgen Brem,[a] Timothy D. W. Claridge,[a] James Spencer,*[b]
Christopher J. Schofield,*[a] and Gary I. Dmitrienko*[c]
Abstract: The most important resistance mechanism to b-
lactam antibiotics involves hydrolysis by two b-lactamase
categories: the nucleophilic serine and the metallo-b-lacta-
mases (SBLs and MBLs, respectively). Cyclobutanones are
hydrolytically stable b-lactam analogues with potential to
inhibit both SBLs and MBLs. We describe solution and
crystallographic studies on the interaction of a cyclobuta-
none penem analogue with the clinically important MBL
SPM-1. NMR experiments using 19F-labeled SPM-1 imply
the cyclobutanone binds to SPM-1 with micromolar affini-
ty. A crystal structure of the SPM-1:cyclobutanone com-
plex reveals binding of the hydrated cyclobutanone
through interactions with one of the zinc ions, stabilisa-
tion of the hydrate by hydrogen bonding to zinc-bound
water, and hydrophobic contacts with aromatic residues.
NMR analyses using a 13C-labeled cyclobutanone support
assignment of the bound species as the hydrated ketone.
The results inform on how MBLs bind substrates and sta-
bilize tetrahedral intermediates. They support further in-
vestigations on the use of transition-state and/or inter-
mediate analogues as inhibitors of all b-lactamase classes.
For more than 70 years, the b-lactams (Figure 1) have been the
most widely used antibacterials. b-Lactam resistance is endem-
ic, substantially due to b-lactamases, which have two mecha-
nistic classes—the nucleophilic serine b-lactamases (SBLs) and
the zinc-dependent metallo-b-lactamases (MBLs) (Figure S1 in
the Supporting Information).[1] Combinations of a b-lactam and
a b-lactam containing SBL inhibitor (e.g. , clavulanic acid) have
been clinically effective;[2] however, the growing dissemination
of new SBLs and MBLs, which are unaffected by such inhibi-
tors, compromises this approach.[3] Carbapenems are broad-
spectrum antibacterials, which were once often used as last-
line treatments. Their widespread use has led to the spread of
SBL and MBL carbapenemases, especially in Gram-negative
bacteria, for example, Escherichia coli and Klebsiella pneumo-
niae.[4] Examples include both Class A and D SBLs and Class B
MBLs (e.g. , IMP-1, VIM-2, SPM-1, NDM-1). Avibactam has been
introduced as a broad-spectrum SBL inhibitor and is the first
clinically useful non-b-lactam b-lactamase inhibitor ;[5] however,
it is a (poor) substrate of some SBLs and most MBLs.[6] There is
thus an unmet need for hydrolytically stable inhibitors active
against both SBLs and MBLs.
One approach to obtain inhibitors active against the two
mechanistically distinct classes of b-lactamases is to mimic the
common tetrahedral intermediate (Figure 2A) or transition
states pre- or succeeding it.[7] Although increasing numbers of
structures describe binding of hydrolyzed b-lactams to MBLs,
progress in inhibitor development is hampered by the absence
of structures describing interactions of MBLs with intact sub-
strates/close analogues. We, and others, have been exploring
cyclobutanone analogues of b-lactams as mechanistic probes
and as templates for broad spectrum b-lactamase inhibition
(Figure 2B). Early compounds, however, manifested only weak
Class A SBL inhibition.[8] Recently, we have found that cyclobu-
tanone analogues of the penems and penams inhibit both
Figure 1. Structures of major classes of clinically used b-lactams, serine b-lac-
tamase inhibitors, cyclobutanone analogue (1), and avibactam.
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SBLs and MBLs.[8a] We identified the cyclobutanone penem an-
alogue 1 (Figure 1) to be the most potent compound tested
against class A and C SBLs, and to have modest inhibition of
the IMP-1 MBL.[8a] However, although we obtained crystallo-
graphic evidence for SBL inhibition, involving binding of the
cyclobutanone by a hemiketal to the nucleophilic serine,[8a] no
information has been available on how cyclobutanones inhibit
MBLs.
The S¼o Paulo MBL (SPM-1) is widely distributed in South
America, Europe and North America, in the Gram-negative
pathogen Pseudomonas aeruginosa.[9] Like other B1 MBLs
(NDM, VIM and IMP),[10] SPM-1 has a binuclear zinc center, but
has loop characteristics of the B2 MBLs, suggesting it is a B1/
B2 hybrid (Figures S2 and 3 in the Supporting Information),
which, consequently, may be challenging to inhibit. To test the
hypothesis that cyclobutanones can act as tetrahedral inter-
mediate analogues for MBLs, we initiated studies on the bind-
ing mode of 1 to SPM-1.
To study binding of 1 to SPM-1, we initially employed
19F NMR (Figure S4 in the Supporting Information). SPM-1 was
selectively labeled at residue 152 on its a3 region, which forms
part of the active site cleft, using cysteine alkylation by 3-
bromo-1,1,1-trifluoroacetone (BTFA) (Figure 3A).[10–12] The
19F NMR spectrum of labeled SPM-1 (SPM-1 Y152C*) manifests
two peaks assigned as corresponding to “closed” (83.3 ppm)
and “open” (72.4 ppm) conformations of the a3 loop (Fig-
ure S5).[11a] Addition of known MBL inhibitors (e.g. , isoquinoline
derivatives, 1,10-o-phenanthroline) results in line broadening
and chemical shift changes in the 19F NMR of a3 variants.[11a] By
contrast, titration of 1 with SPM-1 Y152C* manifests only small
effects on the SPM-1 Y152C* 19F NMR spectra (Figure S5). We
therefore employed a second BTFA-labeled mutant, SPM-1
Y58C*,[11a] incorporating a 19F label on the L3 loop that con-
nects a3 and a4, and which is adjacent to the active site. The
19F NMR spectrum of SPM-1 Y58C*[11a] has one major peak
(83.3 ppm; Figure 3B). Addition of 1 (10 mm) causes a shift
and line broadening, indicating 1 binds in the vicinity of Cys58
in a fast-exchange manner relative to the NMR timescale. Mon-
itoring the concentration dependence of 19F chemical shift
changes on titration of 1 into SPM-1 Y58C* enabled the KD to
be estimated as 227 mm.
We then worked to obtain a structure of cyclobutanone 1
complexed to SPM-1 by soaking crystals with excess inhibitor.
SPM-1 crystallized in its di-zinc “closed” form,[10a] in which the
a3 region folds over the active site, and in a previously unre-
ported space group (P4222). The resolution extended to 1.7 
for uncomplexed crystals and 2.38  for inhibitor soaked crys-
tals (Table S1 in the Supporting Information). Electron density
maps for the latter indicated clear Fo-Fc difference density in
the active site into which 1 was modelled as its hydrated form
(Figure 4A). SPM-1, like other B1 MBLs, has a di-zinc ion active
site with one zinc ion bound at a (normally tetrahedral) tri-his-
tidine site (Zn1) and one in a trigonal bipyramidal site (Zn2)
comprised of conserved Asp, Cys, and His residues (Figure S3).
Wat1 “bridges” the zinc ions and is proposed to act as the “cat-
alytic” nucleophile.[10a] Relative to uncomplexed SPM-1 in the
same crystal form (Table S1), a small (~0.5 ) movement of Zn2
into a more solvent-exposed position in the active site is ob-
served; however, the binding of 1 does not cause significant
structural effects on the metal center with little change in Zn–
Wat1; Zn1–Zn2 or Zn:protein ligand distances. Notable interac-
tions made by 1 are in the vicinity of Zn2. The C4 carboxylate
of 1 makes direct interactions with both Zn2 (2.48  distance)
and Lys219 (2.91 ; Figure 4C), a binding mode likely involved
in substrate carboxylate binding in most B1 MBLs (Figure S7 in
Figure 2. A Proposed binding modes of tetrahedral intermediates in the b-
lactamase-catalyzed hydrolysis of a penem. B Cyclobutanones/penem ana-
logues as potential broad-spectrum SBL and MBL inhibitors.
Figure 3. NMR reveals binding of cyclobutanone 1 to SPM-1. A) View from
an SPM-1 crystal structure showing location of the 19F labels. B) 19F chemical
shift changes for SPM-1 Y58C* (45 mm) on titration with cyclobutanone 1.
C) NMR spectroscopy implies binding of 1 to SPM-1 in its hydrated form.
13C NMR spectrum of 1 (4.2 mm) (green) and 13C NMR spectrum of 1
(4.2 mm) after addition of SPM-1 (0.84 mm) (purple). Circles highlight peaks
assigned to the hydrated form of 1. Assays were buffered with 50 mm Tris-
D11, pH 7.5, in 9:1 H2O:D2O.
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the Supporting Information).[13] By contrast, 1 makes only weak
interactions with Zn1, with the two oxygen atoms of the C6
ketone hydrate with Zn1-oxygen distances of 3.5 and 4.0 . In
contrast to previous predictions about cyclobutanone binding
to MBLs,[14] the Zn-bridging Wat1 is clearly present, potentially
interacting with both the C6 oxygens of 1 (2.7 ; Figure 4C).
SPM-1 is distinguished from other B1 MBLs in possessing a
“wall” of hydrophobic residues involving Phe57 and Tyr58 on
its L3 loop, Phe79 on the loop connecting a5 and a1, and
Phe151 and Tyr152 on the kinked a3 helix in the “closed”
form, as well as Tyr228 on the opposite side of the active site
cleft.[10] Binding of 1 involves hydrophobic interactions with
several of these, notably involving sandwiching of the bicyclic
ring of 1 between the aromatic rings of Tyr58 (consistent with
the 19F-NMR results, Figure 3B) and Tyr228, and edge-face in-
teractions of 1 with Phe79 (Figure 4B). The Tyr152 side chain is
more distant from 1, with its OH group 6.5 (chain A) or 10.8 
(chain B) away from the C7 atom of 1, again consistent with
the 19F NMR results (Figure S5). Notably, despite the clear pres-
ence of 1 at the active sites of both molecules in the asymmet-
ric unit, the conformation of the a3 loop differs substantially in
them (Figure S8 in the Supporting Information) ; compared to
the rest of the structure, this region is flexible (B-factors of
75 2, crystallographic chain A and 64 2, chain B) in support
of the solution studies presented here and previously indicat-
ing a3 flexibility.[10a,11a] By contrast, we do not see evidence for
changes in the L3 loop on binding of 1. The larger 19F NMR
chemical shift changes observed on binding of 1 to SPM-1
Y58C*, compared to SPM-1 Y152C*, can be rationalized by the
closer proximity of residue 58 to the inhibitor binding site, not-
withstanding the more extensive conformational changes ob-
served in the a3 region crystallographically.
Test refinements with the ketone and hydrated forms of 1
yielded similar statistics. We therefore used NMR to investigate
the behavior of 1 in solution both in the presence and absence
of SPM-1. We synthesized 1 in which the C6 (ketone) and adja-
cent C7 dichlorinated carbon atoms were labeled with [13C] .
Under the conditions of the binding studies, [13C]-1 was found
to exist (almost) entirely as its hydrate (consistent with previ-
ous work),[8a] as indicated by the 13C chemical shift (102 ppm)
for C6 and (98.7 ppm) C7, 1JCC=38 Hz. Binding of 1 to SPM-1
under these conditions was confirmed by 13C NMR, in which
the peaks corresponding to hydrated 1 were reduced on addi-
tion of SPM-1 (Figure 3C). Addition of SPM-1 to the sample
yielded no change in the chemical shifts of either the C6 or C7
peaks, with no appearance of a peak around 190 ppm indica-
tive of a ketone at C6. These results support the proposal that
1 is bound to SPM-1 in its hydrated form, although we cannot
exclude initial binding of the ketone form.
It is instructive to consider our results in the context of pos-
sible modes of b-lactam binding, as our work represents the
closest stable analogue of an intact b-lactam for which an MBL
complex structure is currently available. The structure implies
substrate binding includes important interactions of the sub-
strate carboxylate with Zn2 and the adjacent Lys219, as ob-
served for hydrolyzed b-lactams[13] (Figure S7 in the Supporting
Information) and b-lactam analogues[15] (Figure S9), as well as
interactions with hydrophobic elements around the active site
(Figure 4). The structure supports the involvement of these in-
teractions in binding intact b-lactam substrates, and, thus, in
the formation of early-stage complexes in catalysis.
It is notable that the complex with 1 does not feature
strong interactions of the C6 oxygen atoms with Zn1. The Zn1
site is proposed to polarize the b-lactam amide and participate
in activation of the ‘hydrolytic“ water (Wat1).[16] As such, it is
proposed that binding of an intact b-lactam triggers dissocia-
tion of Wat1 from Zn2 to generate a ”terminal“ hydroxide nu-
cleophile on Zn1. The tetrahedral species formed by reaction
of Wat1 with the b-lactam carbonyl is stabilized by Zn1 bind-
ing, as supported by structural analysis of MBLs complexed
with cyclic boronates, which are tetrahedral intermediate ana-
logues (Figure S9 in the Supporting Information).[15] In the hy-
drated cyclobutanone, the C6 oxygen atoms are likely proton-
ated, possibly reducing affinity for Zn1 and instead favoring in-
teraction with Wat1. Further, approach of the non-polar C5H
bond of 1 to Zn2, which may be required to bring Zn1 and
Figure 4. Binding mode of 1 to SPM-1 as observed crystallographically.
A) Cyclobutanone 1 (yellow) binding to the SPM-1 active site of chain A
(grey ribbon). Fo-Fc density (green, contoured at 3s) calculated from the
SPM-1 model in the absence of ligand. Zinc ions and the bridging water/hy-
droxide (Wat1) are grey and red spheres, respectively. B) Interactions be-
tween SPM-1 and cyclobutanone 1 (yellow dashes). C) Interactions of 1 with
SPM-1 in chain A. Distances between 1 (cyan) and the SPM-1 active site are
in magenta. Distances between active site atoms are in blue. The red sphere
represents the bridging water molecule or hydroxide. Numbers indicate dis-
tances in .
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the C6 oxygen atoms into proximity, may be disfavored com-
pared to that of b-lactam derived amide nitrogen.
Inhibition of SBLs by cyclobutanones involves formation of a
hemiketal linkage through reaction of the nucleophilic serine
with the ketone and binding of the resultant tetrahedral spe-
cies in the “oxyanion hole”.[8a] By contrast to the stabilization
of tetrahedral intermediates by SBLs, MBLs are proposed to
preferentially stabilize the ring-opened anionic intermediates
formed after addition of the water/hydroxide (Wat1) nucleo-
phile to the b-lactam carbonyl, but prior to proton transfer to
the lactam-derived nitrogen (Figure S1 in the Supporting Infor-
mation). Interaction of Zn2 with the anionic nitrogen of such
species is proposed to be important in intermediate stabiliza-
tion.[16] Our results, however, show that the SPM-1 active site
can bind with reasonable affinity to a species (i.e. , a hydrated
cyclobutanone) whose tetrahedral carbon (C6) atoms render it
closely (though not perfectly) analogous to the oxyanion inter-
mediate. Taking into consideration the activity of cyclobuta-
nones and boronates against all classes of SBLs,[8a,17] these re-
sults indicate that structures mimicking the tetrahedral oxyan-
ion merit investigation as starting points for potent inhibitors
that are hydrolytically stable and effective against both SBLs
and MBLs.
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